Anticoagulation principles in the management of atrial fibrillation and venous thromboembolism
Dr. Joanne Thanavaro DNP, AGPCNP-BC,AGACNP-BC,DCC, FAANP

Atrial fibrillation and venous thromboembolism are common problems in the primary and acute care setting; both disorders require anticoagulation. Atrial fibrillation (AF) is the most commonly occurring sustained cardiac arrhythmia. The prevalence of AF increases with age and approximately 8% of patients over the age of 80 have this cardiac rhythm. Venous thromboembolism includes deep vein thrombosis and pulmonary embolism. The mortality for DVT and PE is 6% and 12% respectively and the economic burden of VT is greater than 1.5 billion dollars. This session will review the evidenced based guidelines that direct anticoagulation management for clients with atrial fibrillation and venous thromboembolism.

Managing DMII with GLP-1s
Maria Walls

This presentation will discuss the management of Type II Diabetes specifically regarding the GLP-1 Class of medications.

Medication Updates 2019
Golden L. Peters, Pharm.D., BCPS

In 2018, 59 new medications were approved by the FDA and there have been 3 new medications approved in 2019, thus far. The presentation will highlight selected new medications to review each medications indication, specific mechanism of action, dosing information, contraindications, precautions, adverse drug reactions, drug interactions, special administration techniques (when needed), and potential place in current therapy. The presentation will also highlight any special patient instruction or monitoring parameters for providers to take into account when prescribing these new medications. (e.g. injection techniques, priming requirements) New generic medications will be presented, along with any updated FDA recommendations or recent labeling changes to mainstream medications.
All About Opioids
Golden L. Peters, Pharm.D., BCPS

This presentation will focus on general information regarding opioid medications for pain management. The initial selection of an opioid agent for pain management will be reviewed. Transitioning a patient from one opioid agent to another will be discussed, specifically opioid conversion calculations. Opioid allergies and adverse reactions to opioid medications will be compared and contrasted to help identify true opioid allergies and adverse drug reactions, along with management strategies. The concept of opioid de-prescribing will be discussed to help attendees become more familiar with current guideline and/or evidence based recommendations.

Medical Cannabis: Information for the Advanced Practice

In this session participants will receive a review of the NCSBN Guidelines published in July 2018: “The NCSBN National Nursing Guidelines for Medical Marijuana”. Participants will review the History of Cannabis Sativa, the Cannabis Sativa Anatomy (male/female, nodes, stems, fan leaves, flowers, trichomes, cannabinoids and terpenes) and Endocannabinoid System. As part of this presentation there will be an in depth discussion on the therapeutic uses and pharmacological concepts of cannabis with application to case studies.